161 related articles for article (PubMed ID: 33393844)
21. Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma.
Wu PY; Liao YF; Juan HF; Huang HC; Wang BJ; Lu YL; Yu IS; Shih YY; Jeng YM; Hsu WM; Lee H
PLoS One; 2014; 9(2):e88795. PubMed ID: 24586395
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
[TBL] [Abstract][Full Text] [Related]
23. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
24. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
[TBL] [Abstract][Full Text] [Related]
25. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.
Somasundaram DB; Aravindan S; Yu Z; Jayaraman M; Tran NTB; Li S; Herman TS; Aravindan N
BMC Cancer; 2019 Jan; 19(1):106. PubMed ID: 30691436
[TBL] [Abstract][Full Text] [Related]
26. A five-gene signature derived from m6A regulators to improve prognosis prediction of neuroblastoma.
Wang Z; Cheng H; Xu H; Yu X; Sui D
Cancer Biomark; 2020; 28(3):275-284. PubMed ID: 32176634
[TBL] [Abstract][Full Text] [Related]
27. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
28. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
29. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
31. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
32. microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma.
He XY; Tan ZL; Mou Q; Liu FJ; Liu S; Yu CW; Zhu J; Lv LY; Zhang J; Wang S; Bao LM; Peng B; Zhao H; Zou L
Clin Cancer Res; 2017 Jun; 23(11):2905-2918. PubMed ID: 28003306
[No Abstract] [Full Text] [Related]
33. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
Zhong ZY; Shi BJ; Zhou H; Wang WB
J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of a novel stemness-related prognostic model for neuroblastoma using integrated machine learning and bioinformatics analyses.
Xia Y; Wang C; Li X; Gao M; Hogg HDJ; Tunthanathip T; Hulsen T; Tian X; Zhao Q
Transl Pediatr; 2024 Jan; 13(1):91-109. PubMed ID: 38323183
[TBL] [Abstract][Full Text] [Related]
35.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
36. Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma.
Kobayashi K; Mizuta S; Yamane N; Hamabata T; Maihara T; Usami I; Heike T
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e165-e168. PubMed ID: 32032241
[TBL] [Abstract][Full Text] [Related]
37. Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma.
Wang H; Wang X; Xu L; Zhang J; Cao H
BMC Pediatr; 2021 Jun; 21(1):272. PubMed ID: 34116676
[TBL] [Abstract][Full Text] [Related]
38. A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma.
Megiorni F; Colaiacovo M; Cialfi S; McDowell HP; Guffanti A; Camero S; Felsani A; Losty PD; Pizer B; Shukla R; Cappelli C; Ferrara E; Pizzuti A; Moles A; Dominici C
Oncol Rep; 2017 Jul; 38(1):3-20. PubMed ID: 28586032
[TBL] [Abstract][Full Text] [Related]
39. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
[TBL] [Abstract][Full Text] [Related]
40. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]